Berlin Cures hat auf seiner Webseite den momentanen Stand der laufenden Zulassungsverfahren für #BC007 aktualisiert.
Der Beginn einer möglichen Phase III-Studie für #LongCOVID scheint jetzt erst für Q2 2025 vorgesehen zu sein.
First results of #BC007 by Berlin Cures targeting #LongCovid will be expected by end of 2024.
Über eine mögliche Notfallzulassung von #BC007 für #LongCOVID scheint Berlin Cures derzeit keine Angaben machen zu können.
Berlin Cures will start their phase II trial on BC007 for #LongCovid in June. First results are expected at the beginning of next year!
No mention of C19 here but targeted removal of pathogenic AAB’s is the purported mechanism by which BC007 may treat #LongCovid . Given the endless delays that have plagued its development it’s good to know that better-resourced/managed companies are working on similar technology.
berlincures.com/en/news/new-ceo
Bettina Stark-Watzinger Prof. Karl Lauterbach BMBF Bundesgesundheitsministerium
Berlin Cures has uploaded a new article about the appointment of their new CEO, Dr. Oliver von Stein.
The article also confirms that the Phase II-clinical trial with #BC007 for #LongCOVID will start this month.
berlincures.com/en/news/new-ceo